Medy-Tox Inc. Logo

Medy-Tox Inc.

Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.

086900 | KO

Overview

Corporate Details

ISIN(s):
KR7086900008
LEI:
Country:
South Korea
Address:
충청북도 청원군 오창읍 각리1길 78 (주)메디톡스, 청원군
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Medy-Tox Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of aesthetic and therapeutic products. The company's core portfolio consists of botulinum toxin preparations, including its flagship brands Neuronox®, INNOTOX®, and Coretox®, and a range of hyaluronic acid dermal fillers, such as Neuramis®. A pioneer in the South Korean market, Medy-Tox has established a significant presence in the global botulinum toxin industry, distinguished by its robust R&D pipeline and the development of multiple unique formulations. The company also produces a dermocosmetic line under the NEURADERM brand and operates an extensive global network to market its products worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 00:00
Notice of Dividend Amount
중간(분기)배당을위한주주명부폐쇄(기준일)결정
Korean 5.3 KB
2025-08-26 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.7 MB
2025-08-11 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.4 KB
2025-07-22 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 18.2 KB
2025-07-16 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 57.4 KB
2025-07-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 62.4 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.0 MB
2025-05-12 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.5 KB
2025-04-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.3 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.0 KB
2025-03-25 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 28.9 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 26.6 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 604.4 KB
2025-03-13 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 10.9 KB

Automate Your Workflow. Get a real-time feed of all Medy-Tox Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Medy-Tox Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Medy-Tox Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.